Study analysis · The Journal of frailty & aging · 2016
A muscle-building drug that failed its main goal but still changed body composition – here's what happened in a hip replacement trial.
A drug that blocks myostatin (a muscle growth limiter) did not meet its main goal of increasing muscle mass by 2.5% at 12 weeks, but higher doses showed some muscle and fat changes at other time points.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a test to see if a new medicine helps people get stronger after hip surgery. But the main test didn't show a clear win, so we can't say for sure the medicine works. Some smaller tests suggested it might help a little, but those aren't strong enough to prove anything.
What’s the bottom line?
Researchers tested a drug that blocks a protein called myostatin, which normally limits muscle growth. They gave it to people recovering from hip replacement surgery to see if it would help them regain muscle.
How strong is this study?
The study was designed well: patients were randomly split into groups, and neither the patients nor the doctors knew who got the real medicine. This helps make the results fair. But because the main goal wasn't reached, we have to be careful not to trust the smaller findings too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
97 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=400)+17.3/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 573 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Primary endpoint was not met; the study did not show a statistically significant improvement in the primary outcome. Secondary outcomes were exploratory and not adjusted for multiplicity. Therefore, causation cannot be established from this study.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information provided in the abstract.
The abstract does not include a conflict of interest or funding statement. The investigational drug LY2495655 may suggest industry involvement, but no explicit declaration is present.
Key takeaways
- 01
The drug did not meet its main goal: at 12 weeks, muscle mass did not increase by at least 2.5% more than a placebo.
- 02
However, in some measurements at 8 and 16 weeks, higher doses led to small increases in muscle and decreases in fat.
- 03
The improvements were modest and not consistent enough to show a clear benefit for patients.
- 04
The drug did not improve strength or daily function.
Surprising findings
- The primary endpoint failed, but exploratory endpoints showed significant lean mass increases at weeks 8 and 16 for higher doses.It's unusual for a drug to show positive signals at alternate time points after a primary endpoint miss. This raises questions about the optimal timing of therapy and the choice of primary endpoint.
- Despite changes in body composition, there were no improvements in muscle strength or physical function.Conventional wisdom often equates more muscle with better function. This study challenges that assumption, especially in the context of postoperative recovery.
Practical takeaways
For patients recovering from hip replacement, focus on rehabilitation exercises and nutrition rather than experimental drugs, as myostatin antibodies have not proven effective for functional recovery.
This was a Phase 2 trial with a specific population (elective THA); results may not apply to other muscle wasting conditions.
medium confidenceResearchers should consider longer or differently timed treatment regimens and include functional endpoints in future trials of myostatin inhibitors.
The exploratory findings need replication in confirmatory trials before any recommendations can be made.
low confidenceWhy this study matters
Primary Goal Missed: No Significant Muscle Gain at 12 Weeks
The trial enrolled 400 patients aged 69±8 years undergoing total hip arthroplasty. The primary endpoint required a ≥2.5% increase in appendicular lean mass (excluding the operated limb) at week 12 versus placebo. LY2495655 failed to achieve this threshold, meaning the drug did not show a statistically significant benefit on muscle mass at the predefined time point.
This reminds us that even promising biological mechanisms (like blocking myostatin) may not translate into clinical benefits in real-world settings, especially when timing and outcomes are tightly controlled.
Exploratory Signals: Hint of Muscle and Fat Changes at 8 and 16 Weeks
Although the primary endpoint failed, exploratory analyses revealed dose-dependent increases in appendicular lean mass at weeks 8 and 16 for the 105 mg and 315 mg doses. Additionally, the 315 mg dose was associated with a statistically significant decrease in whole body fat mass at those same time points. These findings are hypothesis-generating only.
This shows that drug effects can vary over time. For someone recovering from surgery, timing of treatment may matter more than we think.
No Improvements in Strength or Function
Despite the body composition changes, there were no meaningful differences between groups in muscle strength, physical performance (e.g., gait speed), or self-reported function. This disconnect between muscle mass and actual function is critical.
Many people assume more muscle automatically means stronger and more capable. This study shows that changes in muscle mass do not guarantee functional improvements, especially after surgery.
Side Effects: Injection Site Reactions
Injection site reactions occurred more frequently in the LY2495655 groups compared with placebo. No other safety signals were detected. This suggests the drug was reasonably well-tolerated but had local side effects.
When considering new therapies, the risk-benefit ratio is crucial. Here, the lack of functional benefit combined with injection site reactions makes the current formulation less appealing for patients.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers tested a drug that blocks a protein called myostatin, which normally limits muscle growth. They gave it to people recovering from hip replacement surgery to see if it would help them regain muscle.
Research results
The drug did not meet its main goal: at 12 weeks, muscle mass did not increase by at least 2.5% more than a placebo. However, in some measurements at 8 and 16 weeks, higher doses led to small increases in muscle and decreases in fat.
What this means - more context
The improvements were modest and not consistent enough to show a clear benefit for patients. The drug did not improve strength or daily function.
To assess safety and efficacy of myostatin antibody LY2495655 in patients undergoing elective total hip arthroplasty.
Phase 2 RCT (N=400) did not meet its primary endpoint of ≥2.5% increase in appendicular lean mass at week 12. However, exploratory analyses showed dose-dependent increases in lean mass and decreases in fat mass at weeks 8 and 16 for higher doses. No improvements in strength or function were observed. Injection site reactions were more common with LY2495655.
Methods Used
Randomized, double-blind, placebo-controlled Phase 2 trial at 42 sites in 11 countries. 400 patients ≥50 years scheduled for total hip arthroplasty received subcutaneous placebo or LY2495655 (35, 105, or 315 mg) every 4 weeks for 12 weeks, with follow-up to week 24.
Main Finding
The primary endpoint was not met: LY2495655 did not show a statistically significant increase in appendicular lean mass of at least 2.5% compared with placebo at week 12.
Confidence Level
Moderate – Phase 2 trial with adequate sample size and blinding, but primary endpoint failed; exploratory findings are hypothesis-generating.
Study Flags
Red Flags
- •Primary endpoint not met
- •Exploratory endpoints only (hypothesis-generating)
- •No improvement in functional outcomes
Surprising Findings
The primary endpoint failed, but exploratory endpoints showed significant lean mass increases at weeks 8 and 16 for higher doses.
It's unusual for a drug to show positive signals at alternate time points after a primary endpoint miss. This raises questions about the optimal timing of therapy and the choice of primary endpoint.
Practical Takeaways
For patients recovering from hip replacement, focus on rehabilitation exercises and nutrition rather than experimental drugs, as myostatin antibodies have not proven effective for functional recovery.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 573 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a test to see if a new medicine helps people get stronger after hip surgery. But the main test didn't show a clear win, so we can't say for sure the medicine works. Some smaller tests suggested it might help a little, but those aren't strong enough to prove anything.
Strengths
- Randomized design
- Double-blind
- Placebo-controlled
Weaknesses
- Primary endpoint not met
- Secondary endpoints were exploratory with no multiplicity adjustment
- Only 12-week treatment and 24-week follow-up
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers tested a drug that blocks a protein called myostatin, which normally limits muscle growth. They gave it to people recovering from hip replacement surgery to see if it would help them regain muscle.
Research results
The drug did not meet its main goal: at 12 weeks, muscle mass did not increase by at least 2.5% more than a placebo. However, in some measurements at 8 and 16 weeks, higher doses led to small increases in muscle and decreases in fat.
What this means - more context
The improvements were modest and not consistent enough to show a clear benefit for patients. The drug did not improve strength or daily function.
To assess safety and efficacy of myostatin antibody LY2495655 in patients undergoing elective total hip arthroplasty.
Phase 2 RCT (N=400) did not meet its primary endpoint of ≥2.5% increase in appendicular lean mass at week 12. However, exploratory analyses showed dose-dependent increases in lean mass and decreases in fat mass at weeks 8 and 16 for higher doses. No improvements in strength or function were observed. Injection site reactions were more common with LY2495655.
Methods Used
Randomized, double-blind, placebo-controlled Phase 2 trial at 42 sites in 11 countries. 400 patients ≥50 years scheduled for total hip arthroplasty received subcutaneous placebo or LY2495655 (35, 105, or 315 mg) every 4 weeks for 12 weeks, with follow-up to week 24.
Main Finding
The primary endpoint was not met: LY2495655 did not show a statistically significant increase in appendicular lean mass of at least 2.5% compared with placebo at week 12.
Confidence Level
Moderate – Phase 2 trial with adequate sample size and blinding, but primary endpoint failed; exploratory findings are hypothesis-generating.
Study Flags
Red Flags
- •Primary endpoint not met
- •Exploratory endpoints only (hypothesis-generating)
- •No improvement in functional outcomes
Surprising Findings
The primary endpoint failed, but exploratory endpoints showed significant lean mass increases at weeks 8 and 16 for higher doses.
It's unusual for a drug to show positive signals at alternate time points after a primary endpoint miss. This raises questions about the optimal timing of therapy and the choice of primary endpoint.
Practical Takeaways
For patients recovering from hip replacement, focus on rehabilitation exercises and nutrition rather than experimental drugs, as myostatin antibodies have not proven effective for functional recovery.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 573 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a test to see if a new medicine helps people get stronger after hip surgery. But the main test didn't show a clear win, so we can't say for sure the medicine works. Some smaller tests suggested it might help a little, but those aren't strong enough to prove anything.
Strengths
- Randomized design
- Double-blind
- Placebo-controlled
Weaknesses
- Primary endpoint not met
- Secondary endpoints were exploratory with no multiplicity adjustment
- Only 12-week treatment and 24-week follow-up
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was designed well: patients were randomly split into groups, and neither the patients nor the doctors knew who got the real medicine. This helps make the results fair. But because the main goal wasn't reached, we have to be careful not to trust the smaller findings too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
97 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=400)+17.3/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 573 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Primary endpoint was not met; the study did not show a statistically significant improvement in the primary outcome. Secondary outcomes were exploratory and not adjusted for multiplicity. Therefore, causation cannot be established from this study.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information provided in the abstract.
The abstract does not include a conflict of interest or funding statement. The investigational drug LY2495655 may suggest industry involvement, but no explicit declaration is present.